胰岛素类生长因子结合蛋白2在严重的大动脉狭窄和肺高血压:基于性别的观点
Elke Boxhammer1, Vera Paar1, Kristen Kopp1
1Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical University of Salzburg, 5020 Salzburg, Austria.
International journal of molecular sciences
|August 10, 2024
概括
类似胰岛素的生长因子结合蛋白2 (IGF-BP2) 与男性患有严重大动脉狭窄和肺高血压的结果更差有关. 较高的IGF-BP2水平预测了跨导管大动脉置换后的死亡率.
科学领域:
- 心血管医学 心血管医学
- 生物标志物 生物标志物
- 临床研究 临床研究
背景情况:
- 严重的大动脉狭窄 (AS) 和肺高血压 (PH) 是关键的心血管疾病,需要及时干预.
- 胰岛素类生长因子结合蛋白2 (IGF-BP2) 正在成为心血管疾病的潜在因素.
- 研究IGF-BP2的作用可能会揭示AS和PH的新治疗点.
研究的目的:
- 检查血清IGF-BP2水平与严重AS患者中PH的存在之间的关联,这些患者接受过导管大动脉置换 (TAVR).
- 评估IGF-BP2对该患者队列死亡率的预测价值,特别是在性别和PH状态方面.
主要方法:
- 一个单中心研究涉及102名患有严重AS的患者接受TAVR.
- 心声图被用于诊断PH (sPAP≥40 mmHg).
- 血清IGF-BP2水平在TAVR之前和之后 (24小时,96小时,3个月) 连续测量.
主要成果:
- 与没有PH的患者相比,在所有时间点中,PH患者的IGF-BP2水平显著更高.
- 这些发现对男性有意义,但对女性没有意义.
- 在男性患者中,基线IGF-BP2是TAVR后长期死亡率的独立预测因子,特别是在与PH相结合时.
结论:
- 血清IGF-BP2水平在患有严重AS和并发PH的男性中升高.
- 基线IGF-BP2是重症AS和PH接受TAVR的男性患者死亡率的显著预测因素.
- 对男性IGF-BP2机制的进一步研究可以为TAVR治疗策略提供信息.
更多相关视频
06:51Author Spotlight: Development of a Minimally Invasive Large-Animal Model for Reliable and Reproducible Cardiovascular Research
Published on: October 20, 2023
997
07:41A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
Published on: March 1, 2022
2.9K
相关概念视频
01:30Pulmonary Hypertension: Classification and Pathogenesis
162
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
162
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
147
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
147